Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy with or without rituximab-CVP chemotherapy for stage I-II low grade follicular lymphoma
ACTRN12607000112460Phase 3Active, not recruiting
- Sponsor
- Michael MacManus
- Start
- Feb 2000
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of rituximab, cyclophosphamide, vincristine and prednisolone in follicular lymphoma (FL) (2 arms), sponsored by Michael MacManus. Primary endpoint: Progression-free survival. Started Feb 2000; status: active, not recruiting.
02
Drugs
rituximabcyclophosphamidevincristineprednisolone
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on ACTRN12607000112460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000112460.